Released | Company | Title | Industry | Topic |
---|---|---|---|---|
12 May 2022 10:50 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics AS - Minutes of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
11 May 2022 19:12 CEST |
NYKODE THERAPEUTICS AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
09 May 2022 06:45 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer | 20103010 Biotechnology | Inside information |
06 May 2022 12:45 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
05 May 2022 08:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics AS - Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
19 Apr 2022 08:30 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to host Capital Markets Day | 20103010 Biotechnology | Non-regulatory press releases |
19 Apr 2022 08:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to present at Kempen Life Sciences Conference | 20103010 Biotechnology | Non-regulatory press releases |
08 Apr 2022 19:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
08 Apr 2022 15:35 CEST |
NYKODE THERAPEUTICS AS | Registration of new share capital | 20103010 Biotechnology | Total number of voting rights and capital |
01 Apr 2022 07:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics - full year 2021 financial results and corporate presentation | 20103010 Biotechnology | Non-regulatory press releases |
31 Mar 2022 23:30 CEST |
NYKODE THERAPEUTICS AS | Mandatory notification of exercise of warrants and sale of shares to primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
31 Mar 2022 19:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics reports full year 2021 financial results | 20103010 Biotechnology | Annual financial and audit Reports |
28 Mar 2022 08:00 CEST |
NYKODE THERAPEUTICS AS | Nykode to announce full year 2021 financial results on March 31, 2022 and host webcast presentation on April 1, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
08 Mar 2022 22:30 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
01 Mar 2022 15:11 CET |
NYKODE THERAPEUTICS AS | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
22 Feb 2022 12:30 CET |
NYKODE THERAPEUTICS AS | Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
15 Feb 2022 15:04 CET |
NYKODE THERAPEUTICS AS | Mandatory notification of exercise of warrants | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
14 Feb 2022 06:45 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
11 Feb 2022 06:45 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer | 20103010 Biotechnology | Non-regulatory press releases |
30 Dec 2021 17:31 CET |
NYKODE THERAPEUTICS AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
28 Dec 2021 06:45 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate | 20103010 Biotechnology | Non-regulatory press releases |
22 Dec 2021 11:30 CET |
NYKODE THERAPEUTICS AS | Minutes of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
20 Dec 2021 16:58 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics AS - Mandatory notification of purchase by related party to primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
20 Dec 2021 16:33 CET |
NYKODE THERAPEUTICS AS | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
15 Dec 2021 09:24 CET |
VACCIBODY | Nykode Therapeutics AS - New name registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
15 Dec 2021 08:26 CET |
VACCIBODY | Vaccibody AS*) – Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
15 Dec 2021 08:25 CET |
VACCIBODY | New chairman at Nykode Therapeutics as the Company enters a new stage of internationalization | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
09 Dec 2021 17:49 CET |
VACCIBODY | Registration of new share capital | 20103010 Biotechnology | Total number of voting rights and capital |
03 Dec 2021 17:26 CET |
VACCIBODY | Mandatory notification of trade by primary insiders and related parties | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
03 Dec 2021 16:49 CET |
VACCIBODY | Subscription of warrants | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
30 Nov 2021 13:30 CET |
VACCIBODY | Minutes of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
24 Nov 2021 16:35 CET |
VACCIBODY | Nykode Therapeutics (formerly Vaccibody*)) resolves to issue shares to Regeneron | 20103010 Biotechnology | Total number of voting rights and capital |
23 Nov 2021 06:47 CET |
VACCIBODY | Nykode Therapeutics (formerly Vaccibody*)) enters into multi-target license and collaboration agreement with Regeneron to develop innovative vaccines against cancer and infectious diseases | 20103010 Biotechnology | Non-regulatory press releases |
23 Nov 2021 06:46 CET |
VACCIBODY | Vaccibody AS – Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
23 Nov 2021 06:45 CET |
VACCIBODY | Vaccibody becomes Nykode Therapeutics - a new name and identity to signify a new phase of growth and development | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
17 Nov 2021 07:00 CET |
VACCIBODY | Vaccibody AS - Quarterly report Q3 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
10 Nov 2021 08:00 CET |
VACCIBODY | Vaccibody to participate at Jefferies London Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
03 Nov 2021 16:30 CET |
VACCIBODY | Vaccibody announces first subject dosed in a two-arm phase 1/2 clinical trial with next-generation SARS-CoV-2 vaccine candidates | 20103010 Biotechnology | Non-regulatory press releases |
02 Nov 2021 16:39 CET |
VACCIBODY | Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
01 Nov 2021 17:00 CET |
VACCIBODY | Registration of new share capital | 20103010 Biotechnology | Total number of voting rights and capital |
29 Oct 2021 08:00 CEST |
VACCIBODY | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
14 Oct 2021 08:00 CEST |
VACCIBODY | Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
12 Oct 2021 18:18 CEST |
VACCIBODY | Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
04 Oct 2021 08:00 CEST |
VACCIBODY | Vaccibody to participate at Guggenheim Securities’ 2nd Annual Vaccine and Infectious Disease Days | 20103010 Biotechnology | Non-regulatory press releases |
30 Sep 2021 17:04 CEST |
VACCIBODY | Resolution to issue shares as a consequence of option exercise | 20103010 Biotechnology | Total number of voting rights and capital |
24 Sep 2021 16:40 CEST |
VACCIBODY | Mandatory notification of transfer of shares by primary insider to closely associated person | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
20 Sep 2021 16:54 CEST |
VACCIBODY | Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
10 Sep 2021 17:06 CEST |
VACCIBODY | Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
07 Sep 2021 18:04 CEST |
VACCIBODY | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
26 Aug 2021 06:30 CEST |
VACCIBODY | Vaccibody AS - Quarterly report Q2 2021 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |